Use access key #2 to skip to page content.
$24.62 -0.89 (-3.49%)
7/3/2008 1:00 PM

Amylin Pharmaceuticals, Inc. (AMLN)

CAPS Rating:
**

A biopharmaceutical company committed to improving the lives of people with diabetes, obesity and other diseases through the discovery, development and commercialization of innovative medicines.

View Ticker Page (AMLN)

Results 51 - 55 of 55 : « Previous   6

Recs

0

Avatar mwehrman (< 20) Submitted: 3/01/07 1:52 PM : Outperform Start Price: $37.64 AMLN Score: -24.32

Drug approvals look good and they are targeting large markets - e.g. obesity, etc.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

Avatar mblin13 (< 20) Submitted: 3/01/07 1:11 PM : Underperform Start Price: $37.57 AMLN Score: 24.27

expensive

Report this Post Replies: 0 | Reply | Permalink

Recs

0

Avatar Carol1776 (< 20) Submitted: 2/18/07 5:30 PM : Outperform Start Price: $39.93 AMLN Score: -25.12

Byetta P3 trial with improved dosing regimen completes this year. Patients

Report this Post Replies: 0 | Reply | Permalink

Recs

0

Avatar legal123 (< 20) Submitted: 2/15/07 5:10 PM : Underperform Start Price: $40.05 AMLN Score: 25.37

Remarkable that weekly

Report this Post Replies: 0 | Reply | Permalink

Recs

0

Avatar mgbinsd (< 20) Submitted: 11/16/06 1:06 PM : Outperform Start Price: $44.37 AMLN Score: -34.18

Company continues to have very good results on not only their FDA approved drugs, but their pipeline drugs as well.

Report this Post Replies: 0 | Reply | Permalink

Featured Broker Partners